Skip To Main Content
Eva González-Barca on Muck Rack

Eva González-Barca

As seen in: Wiley Online Library, MDPI, EClinicalMedicine, The Lancet, EMJ- European Medical Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Eva

Contact Eva, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

|
By Byrd J.C, Pau Abrisqueta, Eva González-Barca, Instititut Catala D'Oncologia
| EClinicalMedicine Verified
Research in context Several studies have analysed the combination of inhibitors of BTK (BTKi) with anti-CD20 monoclonal antibodies (mAbs) in patients with chronic lymphocytic leukemia (CLL), both in the frontline and relapsed or refractory settings.
Open in Who Shared Issue with article?

Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study

|
By Pau Abrisqueta, Eva González-Barca, Universitat de Barcelona, Insitut Català d'Oncologia
| The Lancet Verified
Summary Diffuse large B-cell lymphoma comprises nearly 30% of non-Hodgkin lymphoma cases and patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for stem-cell transplantation have few treatment options and poor prognoses.
Open in Who Shared Issue with article?

What to Do When Chimeric Antigen Receptor T Cells Are Not the Most Appropriate Option in Second-Line Diffuse Large B Cell Lymphoma: Current Treatment Options for Transplant-Ineligible Patients

|
By Björn Chapuy, Eva González-Barca, Natacha Bolaños, Gabriel Brisou
| EMJ- European Medical Journal Verified
The patient was not eligible for ASCT due to age and comorbidities, and González-Barca explained that if CAR-T therapy had been available to the patient at this time, they would have been ineligible because they progressed >12 months after 1L therapy. When this patient relapsed in 2020, available treatment options included R-GemOx and R-Benda.
Open in Who Shared Issue with article?
See all 4 licensed articles (6 Total)